All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

MANIFEST trial update: Pelabresib monotherapy for high-risk HU refractory or intolerant ET

Jun 15, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in essential thrombocythemia.

During the European Hematology Association (EHA) 2023 Hybrid Congress, preliminary results from arm 4 of the phase II MANIFEST trial were reported.1 The MANIFEST trial is an ongoing 4-arm global study investigating pelabresib, an oral inhibitor of bromodomain and extra-terminal for the treatment of patients diagnosed with myelofibrosis and essential thrombocythemia (ET).1

Arm 4 of the study is currently evaluating pelabresib as a monotherapy for patients with high-risk ET who are refractory or intolerant to hydroxyurea treatment.1 We summarize the key preliminary findings from this treatment arm in the article below. For more recent developments in myeloproliferative neoplasms presented at the EHA 2023 Hybrid Congress, check out our list of hot abstracts here.

Study design

  • Patients diagnosed with high-risk ET
  • Refractory or intolerant to hydroxyurea
  • At least two symptoms of average score ≥3 or a total symptom score ≥15
  • Platelet count >600 × 109/L
  • 225 mg of pelabresib once daily for 14 days in 21-day cycles
  • Primary endpoint was complete hematologic response at any time


  • The total number of patients in arm 4 was 21.
  • The full list of baseline patient characteristics is shown in Table 1.

Table 1. Baseline patient characteristics*

Characteristic, % (unless otherwise stated)

All patients
 = 21)

Median age, years








Median Hgb, g/dL


Median platelet count, × 109/L


Median WBC count, × 109/L


Median spleen volume, cc


Median TSS


Median prior hydroxyurea duration, months


Patients with ≥2 prior lines of therapy


Prior thrombosis


High-risk MF


Driver mutations









Hgb, hemoglobin; MF, myelofibrosis; TSS, total symptom score; WBC, white blood cell.
*Adapted from Seymour.1


  • The median blood counts at Week 12 were as follows:
    • Median platelet count, 446 × 109/L
    • Median white blood count, 8.2 × 109/L
    • Hemoglobin, 13.0 g/dL
  • The median percentage change in platelet counts at Week 12 was 40%.
  • The median change in white blood cell counts at Week 12 was 8.2 × 109/L.
  • The median hemoglobin remained stable at 13.4 g/dL by Week 24.
  • A total of 14 patients showed a 50% reduction in total symptom score at any time.
  • By Week 12 the median total symptom score had reduced by 31%.
  • Patients experienced an 40% reduction in nuclear factor kappa B-driven cytokine levels.
  • Interleukin-8 gene expression was also reduced posttreatment.


  • Serious adverse events (AEs) occurred in 3 patients.
  • Treatment-emergent AEs were experienced by a further 3 patients, which led to treatment discontinuation.
  • No Grade 5 AEs were reported.
  • The only reported hematologic AE was leukopenia, which was reported in 10% of patients.
  • The most commonly experienced non-hematologic AEs were:
    • Nausea (60%)
    • Diarrhea (35%)
    • Dysgeusia (35%)
    • Constipation (30%)
    • Abdominal pain (25%)
    • Vomiting (25%)
  • Hemorrhagic and thromboembolic events included:
    • Grade 3 pulmonary embolism (5%)
    • Deep vein thrombosis of any grade (5%)
    • Acute myocardial infarction of any grade (5%)
    • Grade 3 hemorrhagic diarrhea (5%)
    • Grade 3 eyelid bleeding (5%)
    • Hematoma of any grade (5%)
    • Hematuria of any grade (5%)
    • Petechia of any grade (5%)
  • Thromboembolic events and eyelid bleeding were not associated with treatment.


Preliminary results from this study highlight hematologic responses and symptom improvements among patients with high-risk ET. Treatment was tolerable and showed potential changes in biomarkers posttreatment. These results continue to support the evidence of a potential rationale for the use of pelabresib therapy for patients with ET.

  1. Seymour C. Pelabresib provides clinical benefit in hydroxyurea-refractory or intolerant high-risk essential thrombocythemia. OncLive. Published Jun 9, 2023. Accessed Jun 14, 2023.


Subscribe to get the best content related to MPN delivered to your inbox